After Moderna's 177% Stock Surge on a Cancer Breakthrough, Wall Street Is Split on What Comes Next

 After Moderna's 177% Stock Surge on a Cancer Breakthrough, Wall Street Is Split on What Comes Next

## The Day Everything Changed for Moderna

For the first time in a long time, Moderna wasn't just a COVID story.

On Wednesday, August 19, 2026, the biotech giant delivered news that sent shockwaves through the medical and financial worlds. Its personalized mRNA cancer vaccine, developed in partnership with Merck, had **succeeded in a Phase 3 melanoma trial**. The results were so compelling that Moderna's stock surged **177%** in a single session, closing at **$174.38**.

The move was historic. Moderna's **491% year-to-date surge** made it the **S&P 500's second-best-performing stock**, trailing only Sandisk's 561% gain. The news unleashed a broad rally across cancer-vaccine, immunotherapy, and advanced-medicine stocks. Merck jumped 13% for its best session since 2009. Biotech funds recorded their strongest sessions in months—or ever.

But the day after the euphoria, Moderna shares fell **12% in pre-market trading**. The question on every investor's mind: **What happens now?**

Here's what Wall Street is actually saying.

---

## The Breakthrough: What Moderna Actually Achieved

### A "Landmark Moment" for Cancer Treatment

The trial, called **INTerpath-001**, evaluated **intismeran autogene (V940/mRNA-4157)** —a personalized mRNA cancer vaccine—in combination with Merck's immunotherapy **Keytruda (pembrolizumab)** for patients with **completely resected stage IIB-IV melanoma**.

The results were striking:

- The combination **reduced the risk of recurrence or death by 49%** (HR=0.51; 95% CI, 0.294-0.887) compared to Keytruda alone

- It **reduced the risk of distant metastasis or death by 59%** (HR=0.411)

- The trial met both its **primary endpoint of recurrence-free survival (RFS)** and its **key secondary endpoint of distant metastasis-free survival (DMFS)**

This is the **first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy**.

"It's a home run, maybe even a grand slam," Dr. Ezekiel Emanuel told Yahoo Finance.

Moderna CEO Stéphane Bancel called it a "pivotal moment for the field of cancer research". "For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality".

The study's principal investigator, Professor Georgina Long, said the results "represent a landmark moment for adjuvant melanoma treatment". She added that the combination "has the potential to establish a new treatment paradigm... helping patients remain cancer-free for longer".

---

## The Hype: What the Cheerleaders Are Saying

### "Cracked the Holy Grail"

Jim Cramer didn't hold back. He said Moderna had **"cracked the holy grail"**. Elon Musk predicted that synthetic RNA would eventually cure many diseases.

Wall Street analysts responded with sweeping upgrades. Here's who got excited:

**William Blair** upgraded Moderna to **Outperform** from Market Perform, calling the result a "clear positive" for revenue diversification.

**Morningstar** more than doubled Moderna's fair value estimate to **$163** from $79. It lifted its 2035 intismeran sales forecast to **$16.8 billion** from $7.2 billion and raised the assumed probability of melanoma approval.

**BofA Securities** called the result a **"watershed moment"** that "fundamentally changed" Moderna's post-COVID story. The firm upgraded the stock to Neutral from Underperform and raised its price target from **$40 to $170**.

Jefferies analyst Tycho Peterson called the update **"an important proof point for mRNA modality beyond legacy COVID"**.

---

## The Reality Check: Why Wall Street Isn't All In

### Most Price Targets Are Still Below the Current Price

Here's the problem: even after the upgrades, **most new price targets remained below Moderna's closing price**.

The consensus, according to 23 analysts polled by S&P Global, remains a **"Hold" rating with an average price target of $78.78**—a staggering **54.82% downside** from the $174.38 close. The targets range from a low of $25 to a high of $170.

Here's how the major firms stack up:

| Firm | Rating | Old Target | New Target | Implied Downside |

|------|--------|------------|------------|------------------|

| **BofA Securities** | Neutral (Upgraded) | $40 | **$170** | -2.5% |

| **Piper Sandler** | Overweight | $77 | **$167** | -4.2% |

| **Jefferies** | Hold | $60 | **$150** | -14% |

| **RBC Capital** | Sector Perform | $45 | **$130** | -25.5% |

| **Goldman Sachs** | Neutral | $67 | **$120** | -31.2% |

| **Morgan Stanley** | Equal Weight | $39 | **$89** | -49% |

| **Citi** | Neutral | — | **$60** | -65.6% |

*Source: *

Even BofA's $170 target—the highest on the Street—implies **2.5% downside** from Wednesday's close. The average target implies shares are worth roughly half of what they traded for on Wednesday.

**The rally left Wall Street behind.**

---

## The Skeptics: Why Some Analysts Are Pumping the Brakes

### "Success in Adjuvant Melanoma Was Already Priced In"

JP Morgan analyst Jessica Fye offered one of the most cautious takes. She noted that Moderna had a **~$25 billion market cap prior to the news** and that **success in adjuvant melanoma was already in their model at an 85% probability of success**.

"Un-risk-adjusting adjuvant melanoma could add ~3% to our valuation," she said, "but we are not surprised to see the stock rallying given the positioning".

For Fye, the **read-across to other indications is critical**. The melanoma data is important, but the real value will come if the platform works in other tumor types.

### "The Full Dataset Matters"

Citi analyst Geoff Meacham struck a similarly cautious tone. While meeting the DMFS endpoint with no new safety signals is "encouraging," he warned that **validation of Moderna's oncology platform will depend on the full dataset** (possibly at ESMO in Madrid, October 23-27) and **evidence that efficacy translates across tumor types**.

For now, Meacham said, "the readout reduces Phase 3 risk without resolving questions around differentiation, commercial uptake, and platform-level read-through".

### "The Debates Are Just Beginning"

BofA's Alex Stranahan, despite being one of the most bullish, acknowledged the uncertainty ahead: "The question now is how big the oncology franchise could get and what areas of upside remain for shares".

He noted that **debates around label expansions and market uptake remain**, even as the overall setup is "fundamentally improved versus 12 months ago".

---

## The Valuation Question: How Much Is Intismeran Actually Worth?

### Morningstar's $16.8 Billion Bet

Morningstar is the most optimistic on intismeran's commercial potential, forecasting **$16.8 billion in sales by 2035**.

But even that bullish forecast comes with caveats. The therapy is **partnered with Merck**, meaning Moderna shares the profits. And the indication—adjuvant melanoma—is "relatively small by immuno-oncology standards," as JP Morgan noted.

### The 177% Run Wasn't Just About Melanoma

The stock's historic surge reflects **investor belief in the platform**, not just the melanoma indication. Moderna has been looking for its next blockbuster after a wildly successful COVID era. The cancer vaccine breakthrough suggests the mRNA platform can be applied beyond infectious diseases.

But as RBC Capital noted, even after calling the data a **"massive scientific breakthrough,"** the firm views the risk-reward as **balanced after the rally**.

---

## What Comes Next: The Catalysts to Watch

### 1. Regulatory Filings

The companies plan to share the data with regulators and file for approval. If approved, intismeran could become the **first mRNA-based cancer treatment** on the market.

### 2. ESMO Data Presentation

The full dataset is expected to be presented at the **European Society for Medical Oncology (ESMO) congress in Madrid, October 23-27**. That will provide the first detailed look at the data and could clarify the magnitude of the benefit.

### 3. Read-Across to Other Tumor Types

The biggest question for long-term investors is whether the platform works in **other cancers**. If intismeran succeeds in lung, bladder, or other immunogenic tumors, the market opportunity expands dramatically.

### 4. Merck's Role

Merck's 13% surge shows investors are betting on the partnership. The companies are co-developing the therapy, and Merck's commercial infrastructure could help drive adoption.

### 5. Profitability

JP Morgan noted that **the launch of intismeran in adjuvant melanoma is key to Moderna returning to profitability**. The company has been losing money since the COVID vaccine boom faded.

---

## Frequently Asked Questions (FAQs)

### 1. What exactly did Moderna announce?

Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran (V940/mRNA-4157), succeeded in a Phase 3 melanoma trial. The combination with Keytruda reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared to Keytruda alone.

### 2. How much did Moderna's stock rise?

Moderna shares surged **177%** on Wednesday, closing at **$174.38**. The stock is now up **491% year-to-date**, making it the S&P 500's second-best performer.

### 3. What is Wall Street's price target for Moderna?

The consensus among 23 analysts is a **"Hold" rating with an average price target of $78.78**—about 55% below Wednesday's close. Targets range from $25 to $170.

### 4. Which analysts are most bullish?

**BofA** raised its target to **$170** (Neutral), **Piper Sandler** to **$167** (Overweight), and **Jefferies** to **$150** (Hold).

### 5. Which analysts are most cautious?

**Citi** kept its target at **$60** (Neutral), implying 66% downside. **Morgan Stanley** raised its target to just **$89** (Equal Weight).

### 6. Is Moderna profitable now?

Not yet. The company has been losing money since the COVID vaccine boom faded. JP Morgan noted that the launch of intismeran is **key to Moderna returning to profitability**.

### 7. When will the full data be released?

The data is expected to be presented at the **ESMO congress in Madrid, October 23-27, 2026**.

### 8. Could this work for other cancers?

That's the big question. Analysts say the **read-across to other indications is critical** to the long-term value of the stock. The companies are already studying intismeran in other tumor types.

---

## Conclusion: A Breakthrough, Not a Guarantee

Moderna's 177% surge was one of the most dramatic single-day moves in biotech history. The data is genuinely impressive—a 49% reduction in recurrence risk in a Phase 3 trial is not something the industry sees every day. The platform validation is real. The scientific implications are profound.

But the stock market is not a science fair.

Wall Street's consensus "Hold" rating and $78.78 average price target tell a story of caution. The analysts who upgraded the stock still left their targets below the closing price. The questions about commercial uptake, label expansion, and platform-level read-through remain unanswered.

Even the most bullish voices—like BofA's $170 target—are essentially saying the stock is fairly valued at Wednesday's price. The skeptics are saying it's dramatically overvalued.

For investors, the message is clear: **the science is a breakthrough. The stock is a bet.**

The full dataset at ESMO will provide more clarity. The regulatory filings will reveal the path to market. The read-across to other cancers will determine whether this is a one-hit wonder or a platform that redefines cancer treatment.

For now, Moderna has done what it needed to do: it has proven that mRNA can fight cancer. The question is whether that proof is worth $174 a share.

---

## Disclaimer

*This article is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. All views expressed are based on publicly available information as of August 20, 2026. Stock prices, analyst ratings, and clinical trial results are subject to change. Past performance is not indicative of future results. The author does not endorse any specific investment strategies or products. Before making any investment decisions based on the content of this article, please consult with qualified professionals who can evaluate your specific situation.*